BioCentury | Feb 26, 2020
Product Development

Subgroup analyses help Vanda hold steady despite Phase III itch miss

...April 2018, the compound missed the primary and secondary endpoints in the Phase II ATOMIK (MTI-103...
BioCentury | Oct 11, 2018
Clinical News

Menlo discontinues serlopitant for chronic cough after Phase II miss

...refractory chronic cough after the compound missed the primary endpoint in the Phase II TUSSIX (MTI-110...
BioCentury | Jun 30, 2018
Finance

Hidden in the rough

...serlopitant (VPD-737) missed the primary and key secondary endpoints in the U.S. Phase II ATOMIK (MTI-103...
BioCentury | Apr 13, 2018
Clinical News

Menlo's serlopitant misses in Phase II for pruritus associated with atopic dermatitis

...serlopitant (VPD-737) missed the primary and key secondary endpoints in the U.S. Phase II ATOMIK (MTI-103...
BioCentury | Apr 9, 2018
Clinical News

Menlo tanks after serlopitant's Phase II miss

...serlopitant (VPD-737) missed the primary and key secondary endpoints in the U.S. Phase II ATOMIK (MTI-103...
BioCentury | Jan 12, 2017
Clinical News

Serlopitant: Ph II AUBURN (MTI-104) started

...Menlo began the double-blind, placebo-controlled, U.S. Phase II AUBURN (MTI-104) trial to evaluate oral serlopitant in...
BioCentury | Jan 12, 2017
Clinical News

Serlopitant: Ph II ATOMIK (MTI-103) started

...Menlo began the double-blind, placebo-controlled, U.S. Phase II ATOMIK (MTI-103) trial to evaluate 2 dose levels...
BioCentury | May 4, 2015
Company News

Affymetrix, MTI deal

...Affymetrix and MTI’s EverGene Ltd. subsidiary partnered for genetic research and personal genomics services in Japan...
...disclose financial details, and MTI could not be reached. Affymetrix Inc. (NASDAQ:AFFX), Santa Clara, Calif. MTI Ltd....
BioCentury | Jun 18, 2012
Company News

Modulation Therapeutics, Multiple Myeloma Research Foundation (MMRF) cancer news

...Modulation Therapeutics received a $500,000 grant from the foundation's Biotech Investment Award program to develop MTI-101...
BioCentury | Jan 9, 2012
Financial News

Ai2 completes venture financing

...1/5/12 Type: Venture financing Raised: L1.8 million ($2.7 million) Investors: North West Fund for Biomedical; MTI WIR...
Items per page:
1 - 10 of 18
BioCentury | Feb 26, 2020
Product Development

Subgroup analyses help Vanda hold steady despite Phase III itch miss

...April 2018, the compound missed the primary and secondary endpoints in the Phase II ATOMIK (MTI-103...
BioCentury | Oct 11, 2018
Clinical News

Menlo discontinues serlopitant for chronic cough after Phase II miss

...refractory chronic cough after the compound missed the primary endpoint in the Phase II TUSSIX (MTI-110...
BioCentury | Jun 30, 2018
Finance

Hidden in the rough

...serlopitant (VPD-737) missed the primary and key secondary endpoints in the U.S. Phase II ATOMIK (MTI-103...
BioCentury | Apr 13, 2018
Clinical News

Menlo's serlopitant misses in Phase II for pruritus associated with atopic dermatitis

...serlopitant (VPD-737) missed the primary and key secondary endpoints in the U.S. Phase II ATOMIK (MTI-103...
BioCentury | Apr 9, 2018
Clinical News

Menlo tanks after serlopitant's Phase II miss

...serlopitant (VPD-737) missed the primary and key secondary endpoints in the U.S. Phase II ATOMIK (MTI-103...
BioCentury | Jan 12, 2017
Clinical News

Serlopitant: Ph II AUBURN (MTI-104) started

...Menlo began the double-blind, placebo-controlled, U.S. Phase II AUBURN (MTI-104) trial to evaluate oral serlopitant in...
BioCentury | Jan 12, 2017
Clinical News

Serlopitant: Ph II ATOMIK (MTI-103) started

...Menlo began the double-blind, placebo-controlled, U.S. Phase II ATOMIK (MTI-103) trial to evaluate 2 dose levels...
BioCentury | May 4, 2015
Company News

Affymetrix, MTI deal

...Affymetrix and MTI’s EverGene Ltd. subsidiary partnered for genetic research and personal genomics services in Japan...
...disclose financial details, and MTI could not be reached. Affymetrix Inc. (NASDAQ:AFFX), Santa Clara, Calif. MTI Ltd....
BioCentury | Jun 18, 2012
Company News

Modulation Therapeutics, Multiple Myeloma Research Foundation (MMRF) cancer news

...Modulation Therapeutics received a $500,000 grant from the foundation's Biotech Investment Award program to develop MTI-101...
BioCentury | Jan 9, 2012
Financial News

Ai2 completes venture financing

...1/5/12 Type: Venture financing Raised: L1.8 million ($2.7 million) Investors: North West Fund for Biomedical; MTI WIR...
Items per page:
1 - 10 of 18